« Back
Home /
SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein,Biotinylated

SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein,Biotinylated

Item no.	40592-V08H-B-20
Manufacturer	Sino Biological
Amount	20 ug
Category	Infectious Diseases Viral Infections Coronavirus (COVID-19) Peptides & Proteins Recombinant Proteins
Type	Proteins
Specific against	other
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Available
Manufacturer - Category	Protein
Purity	> 95 % as determined by SDS-PAGE
Endotoxin	< 1.0 EU per ug protein as determined by the LAL method.
Activity	Testing in progress
Protein Construction	A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The purified protein was biotinylated in vitro.
Expressed Host	HEK293 Cells
Predicted N Terminal	Arg319
Molecule Mass	The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (RBD, His Tag) consists of 234 amino acids and predicts a molecular mass of 23.54 kDa.
Formulation	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
Shipping	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20C to -80C Store it under sterile conditions at -20C to -80C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
References	Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35. Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36. Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 20 ug

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question